#ASCO23 (Photo: Senior editor Max Gelman for Endpoints News)

Mod­er­na, Mer­ck say their can­cer vac­cine re­duces metas­tases by 65% in PhII study of high-risk melanoma: #AS­CO23

CHICA­GO — Mod­er­na’s am­bi­tions to chart a fu­ture be­yond Covid-19 shots and un­leash its mR­NA tech­nolo­gies on can­cer just got a lot brighter.

The mR­NA pi­o­neer and Mer­ck an­nounced new da­ta on Mon­day at AS­CO’s an­nu­al meet­ing for their per­son­al­ized can­cer vac­cine — made from mR­NA-en­cod­ing mol­e­c­u­lar mugshots unique to an in­di­vid­ual’s tu­mor. In pa­tients who un­der­went surgery to re­move high-risk skin can­cer, a com­bi­na­tion of the cus­tom shot and Mer­ck’s im­munother­a­py Keytru­da sig­nif­i­cant­ly re­duced the risk of de­vel­op­ing dead­ly metas­tases by 65% com­pared to pa­tients tak­ing Keytru­da alone.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.